New York, Sept. 30, 2022 (GLOBE NEWSWIRE) — Reportlinker.com Announces Release of “Technology Growth Opportunities for Exosome-Mediated Drug Delivery” Report – https://www.reportlinker.com/p06323902/?utm_source=GNW
The widely explored concepts of nanomedicine, nucleic acid therapeutics, and cell-free vaccines have bolstered the inclusion of exosomes in the delivery of new drug modalities.
Non-immunogenicity, biocompatibility and stability are key characteristics that make exosomes attractive as carriers in the biopharmaceutical sector.
As such, microRNAs, small interfering RNAs, the CRISPR-Cas9 system, viral vectors, antisense oligonucleotides, messenger RNA (mRNA) vaccines, heteroduplexes, surface antigens and protein antibodies have emerged as cargo modalities, packaged endogenously or exogenously in natural or artificial products. exosomes.
Exosomes alleviate the problems of stability, low bioavailability, targeting, reduced gene expression, membrane uptake, and cellular degradation that other nanocarriers face in drug delivery modalities.
There is a growing body of research and clinical evidence to support the immense value of exosomes in delivering mRNA vaccines, gene editing tools, gene therapy, and disease-related small proteins to treat life-threatening conditions.
Exosomes are also used to develop mRNA and other advanced therapeutic formulations that can be delivered by more patient-compliant routes, such as oral and intranasal.
These extracellular vesicles are designed on the surface to maximize payload efficiency and targeted delivery.
Increasing R&D on delivery specificity, cellular uptake and exosome signaling effect is accelerating the development of new exosome-mediated drug delivery technologies for better patient outcomes.
The United States has become the hub of the exosome drug delivery industry, with many private and academic institutions conducting research and adopting technologies.
Europe is also seeing a considerable amount of R&D activity as intensive collaborations accelerate the development of exosomes as nanocarriers.
The scalability of exosome production remains a problem, but biotech companies are tackling it by building new manufacturing platforms and searching for new sources of extracellular vesicles.
These engines have opened up new growth opportunities to access non-drug targets associated with rare and fatal diseases.
This research provides an overview of emerging modalities provided by exosomes at preclinical or clinical stages, highlighting technology roadmaps, market trends, and latest research findings.
The study examines the different routes of administration to inject these fractions into the human body and the notable R&D collaborations and licensing agreements between pharmaceutical companies, biotechnology companies and academic partners for the development of commercial products after transfer. of technology.
Codiak BioSciences, Capricor Therapeutics and Evox Therapeutics are among key companies with numerous pipeline candidates, significant investments and strategic R&D partnerships in the area of drug delivery via exosomes for disease indications such as cancer, COVID-19, rare diseases and neurological diseases. troubles.
This study completes the analysis with growth opportunities for the clinical translation of exosome nanocarriers.
Read the full report: https://www.reportlinker.com/p06323902/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.